ResMed Inc. has been a focus of recent market discussions, with fluctuations in share prices and various transactions prompting reconsiderations of the medical device company's valuation and investment potential. Notably,
Lbp Am Sa acquired 18,142 shares, and
Hendershot Investments Inc increased their holdings. Conversely,
Sumitomo Mitsui Trust Group Inc and
Robeco Institutional Asset Management B.V sold their shares, and
ResMed's CEO Michael Farrell sold 4,991 shares.
JPMorgan Chase & Co is now covering ResMed, which was also upgraded to 'Buy'.
Q2 & Q3 earnings exceed estimates, contributing to strong revenue growth and strategic innovations predicted for the fiscal year 2026. The company's valuation remains a topic of interest amongst investors, especially due to recent share price weakness and strong financials. ResMed's
CFO Sandercock participated in open market trading selling 1,000 shares. Institutions like
Aberdeen Group plc and
J. Safra Sarasin Holding AG have sold significant numbers of shares, while
Element Squared LLC and
Runnymede Capital Advisors Inc joined the list of new investors.
Resmed RMD News Analytics from Fri, 01 Aug 2025 07:00:00 GMT to Sat, 18 Apr 2026 08:11:48 GMT -
Rating 3
- Innovation 5
- Information 4
- Rumor -1
